| Species Reactivity | Human |
| Clone | eblasakimab |
| Source/Isotype | Human IgG4(S228P), Kappa |
| Application | Bioactivity-ELISA |
| Target | Detects IL-13RA1 |
| Gene | IL-13RA1 |
| Other Names | IL13RA1, CD213A1, IL-13Ra, NR4, RP13-128O4.2, IL13Rα1 |
| Gene ID | 3597 (Human) |
| Background | IL13RA1 is a component of the type II IL-4 receptor. It is a single-pass transmembrane protein encoded by the IL13RA1 gene and expressed on various cells, including macrophages, dendritic cells, some lymphocytes, and some non-hematopoietic cells. It partners with IL4Rα to form the IL-13 receptor, modulating allergic inflammation, Th2 responses, and tissue remodeling. Dysregulation of IL-13 signaling via IL13RA1 links to atopy and fibrosis. IL-13 binding to the IL13RA1/IL4Rα complex activates JAK-STAT signaling, mainly inducing STAT6 phosphorylation and transcription of IL-4/IL-13–responsive genes. It also engages PI3K-AKT and MAPK pathways, affecting epithelial barrier, mucus production, and chemokine/cytokine expression. Cross-talk with IL-4 can amplify responses. Aberrant IL-13/IL13RA1 signaling is associated with allergic diseases, fibrosis, and inflammation, making this axis a therapeutic target. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | eblasakimab |
| Source/Isotype | Human IgG4(S228P), Kappa |
| Application | Bioactivity-ELISA |
| Target | Detects IL-13RA1 |
| Gene | IL-13RA1 |
| Other Names | IL13RA1, CD213A1, IL-13Ra, NR4, RP13-128O4.2, IL13Rα1 |
| Gene ID | 3597 (Human) |
| Background | IL13RA1 is a component of the type II IL-4 receptor. It is a single-pass transmembrane protein encoded by the IL13RA1 gene and expressed on various cells, including macrophages, dendritic cells, some lymphocytes, and some non-hematopoietic cells. It partners with IL4Rα to form the IL-13 receptor, modulating allergic inflammation, Th2 responses, and tissue remodeling. Dysregulation of IL-13 signaling via IL13RA1 links to atopy and fibrosis. IL-13 binding to the IL13RA1/IL4Rα complex activates JAK-STAT signaling, mainly inducing STAT6 phosphorylation and transcription of IL-4/IL-13–responsive genes. It also engages PI3K-AKT and MAPK pathways, affecting epithelial barrier, mucus production, and chemokine/cytokine expression. Cross-talk with IL-4 can amplify responses. Aberrant IL-13/IL13RA1 signaling is associated with allergic diseases, fibrosis, and inflammation, making this axis a therapeutic target. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
